InflaRx Announces First Patient Dosed in Phase 2a Study for CSU and HS

InflaRx N.V. has reached a significant milestone by dosing the first patient in its Phase 2a basket study. This study is focused on investigating the efficacy and safety of the company's oral C5aR inhibitor, INF904, in treating chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS). The initiation of this study marks an important step forward in the development of new therapeutic options for patients suffering from these challenging conditions.